# A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;

> **NCT04939363** · PHASE2 · COMPLETED · sponsor: **Bnai Zion Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Richter's Syndrome

## Interventions

- **COMBINATION_PRODUCT:** Obinutuzumab with Ibrutinib and Venetoclax

## Key facts

- **NCT ID:** NCT04939363
- **Lead sponsor:** Bnai Zion Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-08
- **Primary completion:** 2024-10-09
- **Final completion:** 2024-12-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939363, "A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04939363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*